Vaishnaw Akshay
Known title: President, R&DCIK: 0001458494
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Transaction History
| SRRK | ▼ Sell | Open Market | 12,246 | $607K | 4/16/2026 | View on chart |
| SRRK | ▲ Buy | Grant | 47,021 | $0 | 2/9/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 20,438 | $873K | 1/13/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 1,620 | $49K | 5/29/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 5,130 | $152K | 5/29/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 100,000 | $0 | 4/27/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 500,000 | $0 | 4/27/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 13,500 | $0 | 6/27/2024 | View on chart |
| ALNY | ▼ Sell | Open Market | 17 | $3K | 8/4/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 771 | $142K | 8/4/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,869 | $347K | 8/4/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,107 | $206K | 8/4/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 101 | $19K | 8/4/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 192 | $36K | 8/4/2023 | View on chart |
| ALNY | ▲ Buy | Grant | 5,082 | $0 | 8/3/2023 | View on chart |
| ALNY | ▲ Buy | Grant | 3,859 | $0 | 8/3/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 197 | $38K | 4/27/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 910 | $176K | 4/27/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,013 | $197K | 4/27/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 104 | $20K | 4/27/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 168 | $33K | 4/27/2023 | View on chart |
| ALNY | ▲ Buy | Grant | 5,312 | $0 | 4/26/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 19,447 | $4.2M | 2/10/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 4,302 | $934K | 2/10/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,709 | $364K | 2/10/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 2,307 | $494K | 2/10/2023 | View on chart |
| ALNY | ▼ Sell | Open Market | 10,279 | $2.2M | 2/10/2023 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 30,913 | $1.9M | 2/10/2023 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 1,124 | $100K | 12/5/2022 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 2,368 | $100K | 12/5/2022 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 1,587 | $100K | 12/5/2022 | View on chart |
| ALNY | ▼ Sell | Tax Withholding | 1,324 | $299K | 12/5/2022 | View on chart |
| ALNY | ▼ Sell | Tax Withholding | 5,479 | $1.0M | 8/4/2022 | View on chart |
| ALNY | ▼ Sell | Tax Withholding | 195 | $41K | 8/4/2022 | View on chart |
| ALNY | ▼ Sell | Tax Withholding | 180 | $38K | 8/4/2022 | View on chart |
| ALNY | ▼ Sell | Tax Withholding | 198 | $42K | 8/4/2022 | View on chart |
| ALNY | ▲ Buy | Grant | 5,083 | $0 | 8/3/2022 | View on chart |
| ALNY | ▲ Buy | Grant | 3,859 | $0 | 8/3/2022 | View on chart |
| ALNY | ▲ Buy | Grant | 4,241 | $0 | 8/3/2022 | View on chart |
| ALNY | ▼ Sell | Open Market | 137 | $26K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 73 | $14K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 1,000 | $191K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 145 | $28K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 303 | $59K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 124 | $23K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 142 | $27K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 125 | $24K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 73 | $14K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 126 | $24K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 144 | $27K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 144 | $27K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 5 | $951 | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 130 | $24K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 127 | $24K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 73 | $14K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Open Market | 8 | $2K | 12/23/2021 | View on chart |
| ALNY | ▼ Sell | Tax Withholding | 2,415 | $457K | 12/22/2021 | View on chart |
| ALNY | ▼ Sell | Tax Withholding | 1 | $191 | 12/22/2021 | View on chart |
| ALNY | ▼ Sell | Tax Withholding | 122 | $23K | 12/22/2021 | View on chart |
| ALNY | ▲ Buy | Grant | 5,417 | $0 | 12/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA
Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.